SCHEMBL5652375

SCHEMBL5652375

C=CCNC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 2/20 0.45
ALOX15 P16050 2/20 0.42
KDM4E B2RXH2 3/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
HPGD P15428 6/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
TP53 P04637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649437 0.86 HPGD (0.44) SMN1; SMN2KMT2APOLBKDM4EHPGD
SCHEMBL5654415 0.83 HIF1A (0.38) SMN1; SMN2MEN1KMT2APOLBKDM4E
SCHEMBL5652095 0.82 HPGD (0.45) SMN1; SMN2MEN1KMT2AALOX15KDM4E
SCHEMBL5652629 0.82 PLK1 (0.41) MEN1KMT2AKDM4EHTTHPGD
SCHEMBL5651612 0.81 CNR2 (0.41) KDM4EHPGDALDH1A1
SCHEMBL5650705 0.80 KMT2A (0.43) SMN1; SMN2MEN1KMT2AKDM4ETSHR
SCHEMBL5653732 0.80 PARP1 (0.47) MEN1KMT2APOLBKDM4EHPGD
SCHEMBL5651037 0.79 PARP1 (0.46) MEN1KMT2APOLBKDM4EHPGD
SCHEMBL5649654 0.78 ALDH1A1 (0.44) MEN1KMT2AKDM4EHPGDCYP1A2
SCHEMBL5652540 0.77 HPGD (0.52) SMN1; SMN2MEN1KMT2AKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 SMN1; SMN2 3476/4885MEN1 4697/4885KMT2A 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.